SCHEMBL450134

SCHEMBL450134

O=c1ccc2c(O)cccc2o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.60
CA9 Q16790 3/20 0.60
CA1 P00915 2/20 0.60
CYP2A6 P11509 6/20 0.55
MAOA P21397 3/20 0.52
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
KMT2A Q03164 1/20 0.48
CYP3A4 P08684 4/20 0.47
GAA P10253 3/20 0.47
LMNA P02545 2/20 0.47
MCL1 Q07820 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
CYP1A2 P05177 1/20 0.47
BCHE P06276 1/20 0.47
GLA P06280 1/20 0.47
AKR1B1 P15121 1/20 0.47
ALOX15 P16050 1/20 0.47
ACHE P22303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coumarin SCHEMBL7644084 0.78 CA12 (0.67) CA12CA9CA1MAOAALDH1A1
SCHEMBL5542888 0.77 CYP2A6 (0.56) CA12CA9CA1CYP2A6MAOA
SCHEMBL11035090 0.75 CYP2A6 (0.55) CA12CA9CA1CYP2A6MAOA
SCHEMBL11034294 0.75 CYP2A6 (0.55) CA12CA9CA1CYP2A6MAOA
SCHEMBL15842364 0.75 CYP2A6 (0.55) CA12CA9CA1CYP2A6MAOA
SCHEMBL2670683 0.75 NQO1 (0.62) CA12CA9CA1CYP2A6MAOA
SCHEMBL8252613 0.75 CYP2A6 (0.55) CA12CA9CA1CYP2A6MAOA
SCHEMBL546445 0.75 CYP2A6 (0.59) CA12CA9CA1CYP2A6MAOA
4-Hydroxycoumarins SCHEMBL131312 0.75 CA12 (1.00) CA12CA9CA1MAOAALDH1A1
SCHEMBL6783654 0.75 ALDH1A1 (0.53) CA12CA9CA1CYP2A6MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714452-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS Gilead Sciences, Inc. (US) 2026-03-25 EP claimed
US-20250064758-A1 ANTIVIRALS TARGETING PHOSPHATIDIC ACID PHOSPHATASE (PAP) CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (CN) 2025-02-27 US claimed
CN-117721161-A Biological-based multifunctional anti-aging auxiliary agent, and preparation method and application thereof 四川大学 2024-03-19 CN claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
US-11660307-B2 Methods for treating SARS CoV-2 infections GILEAD SCIENCES, INC. (US) 2023-05-30 US claimed
CN-106179495-B The synthetic method and its catalyst for synthesizing of a kind of loop coil acenaphthylene pyran derivate, the derivative 马鞍山市泰博化工科技有限公司 2018-09-14 CN claimed
CN-106179495-A A kind of volution acenaphthylene pyran derivate, the synthetic method of this derivant and catalyst for synthesizing thereof 马鞍山市泰博化工科技有限公司 2016-12-07 CN claimed
CN-101497593-B 5-hydroxy coumarin and pyranoid type coumarin compounds, synthesizing method and use UNIV SOUTH CHINA TECH 2011-09-21 CN claimed
CN-101497593-A 5-hydroxy coumarin and pyranoid type coumarin compounds, synthesizing method and use UNIV SOUTH CHINA TECH (CN) 2009-08-05 CN claimed
CN-1225998-C Cigarette additive extracted from natural plant, and extracting method and use in cigarette thereof SHENNONG YANKE TECHNOLOGY CO L (CN) 2005-11-09 CN claimed
CN-1488300-A Cigarette additive extracted from natural plant, and extracting method and use in cigarette thereof 广东神农烟科技术有限公司 2004-04-14 CN claimed
US-5608085-A Synthesis of optically active calanolides A and B and enantiomers and related compounds THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1997-03-04 US claimed
WO-1996026934-A1 SYNTHESIS OF OPTICALLY ACTIVE CALANOLIDES A AND B AND ENANTIOMERS AND RELATED COMPOUNDS THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1996-09-06 WO claimed
US-5432014-A Flat display element SANYO ELECTRIC CO., LTD. (JP) 1995-07-11 US claimed
EP-4346772-B1 PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS GILEAD SCIENCES INC (US) 2026-04-01 EP disclosed
EP-4714452-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS Gilead Sciences, Inc. (US) 2026-03-25 EP disclosed
EP-4132651-B1 INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBANUCLEOSIDE ANALOGS GILEAD SCIENCES INC (US) 2026-03-18 EP disclosed
US-3994828-A Nonabsorbable antioxidant DYNAPOL CORPORATION (US) 1976-11-30 US disclosed
US-3973979-A MAGENTA DYES, SILVER HALIDE EMULSIONS AGFA-GEVAERT, A.G. (DT) 1976-08-10 US disclosed
US-3965122-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064758-A1 ANTIVIRALS TARGETING PHOSPHATIDIC ACID PHOSPHATASE (PAP) ACE, ACE2, PPP3CA CA12 2096/4885CA9 3077/4885CA1 4302/4885
US-11660307-B2 Methods for treating SARS CoV-2 infections ACE2, ACE, PNP CA12 770/4885CA9 1275/4885CA1 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.